Archives of Toxicology

, Volume 40, Issue 2, pp 109–118 | Cite as

Bile acid conjugation in the chimpanzee: effective sulfation of lithocholic acid

  • M. Schwenk
  • A. F. Hofmann
  • G. L. Carlson
  • J. A. Carter
  • F. Coulston
  • H. Greim
Article
Received:

Abstract

To characterize the hepatic biotransformation in the chimpanzee of the primary bile acid chenodeoxycholic acid (chenic) and its major bacterial metabolite lithocholic acid (lithocholic) a mixture of tracer amounts of14C-lithocholic and3H-chenic was injected intravenously into two animals with a bile fistula; the chemical form of radioactivity appearing in bile was inferred using thin layer chromatography. About 80% of chenic, and 70% of lithocholic was recovered in 90 min. Chenic was completely conjugated in bile, appearing predominantly as chenyltaurine (52%) and chenylglycine (37%). An unidentified conjugate (about 11%) was also found. Lithocholic was excreted completely as taurine and glycine conjugates, but the majority (63%) of conjugates was sulfated. Sulfation increased progressively with time, and lithocholylglycine was sulfated more than lithocholyltaurine. We conclude that the chimpanzee is similar to man in that the secondary bile acid lithocholic is efficiently sulfated. The chimpanzee thus differs from the baboon and rhesus monkey which sulfate lithocholic poorly. However, the chimpanzee differs from man and is similar to the baboon and rhesus monkey in showing preferential conjugation of bile acids with taurine. The results imply that hepatotoxicity caused by chenic, which is well documented in the rhesus monkey and baboon and has been related to defective lithocholic sulfation, should not occur in the chimpanzee.

Key words

Chenodeoxycholic acid Chimpanzee Conjugation Lithocholic acid Sulfation Toxicity 

Zusammenfassung

Um im Schimpansen die hepatische Biotransformation der primären Gallensäure Chenodeoxycholsäure und deren wichtigstem bakteriellen Metaboliten, Lithocholsäure zu charakterisieren, wurde ein Gemisch aus Spurenmengen von14C-Lithocholsäure und3H-Chenodeoxycholsäure intravenös in zwei Tiere mit Gallenfistel injiziert. Die chemische Form der Radioaktivität, die in der Galle erschien, wurde dünnschichtchromatographisch ermittelt. Etwa 80% der Chenodeoxycholsäure und 70% der Lithocholsäure wurden innerhalb von 90 min ausgeschieden. Die Chenodeoxycholsäure war vollständig konjugiert und erschien vorwiegend als Chenyltaurin (52%) und Chenylglycin (37%). 11% erschienen in einer Form, die bisher nicht identifiziert wurde. Lithocholsäure wurde vollständig als Taurin- und Glycinkonjugat in die Galle eliminiert; der größte Teil (63%) war zusätzlich sulfatiert. Die Sulfatierung nahm stetig mit der Zeit zu und Lithocholylglycine wurde stärker sulfatiert als Lithocholyltaurin.

Wir schließen aus diesen Befunden, daß der Schimpanse mit dem Menschen vergleichbar ist, indem er Lithocholsäure effektiv sulfatiert. Dadurch unterscheidet sich der Schimpanse vom Rhesusaffe und Baboon, die die Lithocholsäure nur in geringem Maße sulfatieren. Jedoch unterscheidet sich der Schimpanse auch vom Menschen und ähnelt dem Rhesusaffen und dem Baboon, indem er Gallensäure vorwiegend mit Taurin konjugiert. Die Ergebnisse lassen den Schluß zu, daß die Hepatotoxizität, die im Rhesusaffe und Baboon durch Chenodeoxycholat hervorgerufen wird, und auf eine geringe Sulfatierung der Lithocholsäure zurückgeführt wird, beim Schimpansen nicht bestehen sollte.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allan, R. N., Thistle, J. L., Hofmann, A. F.: Lithocholate metabolism during chenotherapy for gall-stone dissolution. II. Absorption and sulfation. Gut17, 413–419 (1976b)PubMedGoogle Scholar
  2. Allan, R. N., Thistle, J. L., Hofmann, A. F., Carter, J. A., Yu, P. Y. S.: Lithocholate metabolism during chenotherapy for gallstone dissolution. I. Serum levels of sulfated and unsulfated lithocholates. Gut17, 405–412 (1976a)PubMedGoogle Scholar
  3. Back, P.: Bile acid glucuronides. III. Isolation and identification of a chenodeoxycholic acid glucuronide from human plasma in intrahepatic cholestasis. Hoppe-Seylers Z. physiol. Chem.357, 213–217 (1976)PubMedGoogle Scholar
  4. Barbara, L., Roda, E., Roda, A., Sama, C., Festi, D., Mazzella, G., Aldini, R.: The medical treatment of cholesterol gallstones: experience with chenodeoxycholic acid. Digestion14, 209–219 (1976)PubMedGoogle Scholar
  5. Bateson, M. C., Hopwood, D., Bouchier, I. A. A. D.: Effect of gallstone-dissolution therapy on human liver structure. Digestive diseases22, 293–299 (1977)CrossRefGoogle Scholar
  6. Bell, G. D., Mok, H. Y. I., Thwe, M., Murphy, G. M., Henry, K., Dowling, R. H.: Liver structure and function in cholelithiasis I. Effect of chenodeoxycholic acid. Gut15, 165–172 (1974)PubMedGoogle Scholar
  7. v. Berge Henegouwen, G. P., Brandt, K. H., Eyssen, H., Parmentier, G.: Sulfated and unsulfated bile acids in serum, bile and urine of patients with cholestasis. Gut17, 861–869 (1976)PubMedGoogle Scholar
  8. Cass, O. W., Cowen, A. E., Hofmann, A. F., Coffin, S. B.: Thin layer Chromatographic separation of sulfated and unsulfated lithocholic acid and its glycine and taurine conjugates. J. Lipid Res.16, 159–160 (1975)PubMedGoogle Scholar
  9. Cowen, A. E., Hofmann, A. F., Hachey, D. L., Thomas, P. J., Belobaba, D. T. E., Klein, P. D., Tokes, L.: Synthesis of 11,12-2H2-labelled chenodeoxycholic and lithocholic acids. J. Lipid Res.17, 231–238 (1976)PubMedGoogle Scholar
  10. Cowen, A. E., Korman, M. G., Hofmann, A. F., Cass, O. W.: Metabolism of lithocholate in man I. Biotransformation and biliary excretion of intravenously administered lithocholate, lithocholylglycine and their sulfates. Gastroenterology69, 59–66 (1975a)PubMedGoogle Scholar
  11. Cowen, A. E., Korman, M. G., Hofmann, A. F., Cass, O. W., Coffin, S. B.: Metabolism of lithocholate in healthy man. II. Enterohepatic circulation. Gastroenterology69, 67–76 (1975b)PubMedGoogle Scholar
  12. Coyne, M. J., Bonorris, G., Chung, A., Goldstein, L. I., Lahana, D., Schoenfield, L. J.: Treatment of gallstones with chenodeoxycholic acid and phenobarbital. New Engl. J. Med.292, 604–607 (1975)PubMedGoogle Scholar
  13. Danielsson, H., Einarsson, K.: Formation and metabolism of bile acids. Biol. Basis Med.5, 279–315 (1969)Google Scholar
  14. Danzinger, R. G., Hofmann, A. F., Schoenfield, L. S., Thistle, S. L.: Effect of oral chenodeoxycholic acid on bile acid kinetics and biliary lipid composition in women with cholelithiasis. J. clin. Invest.52, 2809–2821 (1973)PubMedGoogle Scholar
  15. Dyrszka, H., Salen, G., Chen, T.: Toxicity of chenodeoxycholic acid in the rhesus monkey. Gastroenterology69, 333–337 (1975)PubMedGoogle Scholar
  16. Dyrszka, H., Salen, G., Zaki, F. G., Chen, T., Mosbach, E. H.: Hepatic toxicity in the rhesus monkey treated with chenodeoxycholic acid for 6 months; biochemical and ultrastructural studies. Gastroenterology70, 93–104 (1976)PubMedGoogle Scholar
  17. Fischer, D. C., Cooper, N. S., Rothschild, M. A., Mosbach, E. H.: Effect of dietary chenodeoxycholic acid and lithocholic acid in the rabbit. Amer. J. dig. Dis.19, 877–886 (1974)CrossRefPubMedGoogle Scholar
  18. Fröhling, W., Stiehl, A.: Bile salt glucuronides: Identification and quantitative analysis in the urine of patients with cholestasis. Europ. J. clin. Invest.6, 67–74 (1976)PubMedGoogle Scholar
  19. Fromm, A., Eschler, A., Töllner, D., Canzler, H., Schmidt, F. W.: Untersuchungen zur Gallensteinauflösung in vivo. Dtsch. Med. Wschr.100, 1619–1624 (1975)PubMedGoogle Scholar
  20. Gadacz, T. R., Allan, R. N., Mack, E., Hofmann, A. F.: Impaired lithocholate sulfation in the rhesus monkey: a possible mechanism for chenodeoxycholate toxicity. Gastroenterology70, 1125–1129 (1976)PubMedGoogle Scholar
  21. Gerolami, A., Sarles, H., Brette, R., Paraf, A., Rautureau, J., Debray, C. H., Bermann, C., Etienne, J. P., Chaput, J. C., Petite, J. P.: Controlled trial of chenodeoxycholic acid therapy for radiolucent gallstones: A multicenter study. Digestion (in press)Google Scholar
  22. Goldstein, L.: Animal toxicology studies of chenic acid. Report of the Biostatistic Center, National Cooperative Gallstone Study, Document 87. (in press)Google Scholar
  23. Hepner, G. W., Sturman, J. A., Hofmann, A. F., Thomas, P. J.: Metabolism of steroid and amino acid moieties of conjugated bile acids in man III. Taurocholic acid. J. clin. Invest.52, 715–724 (1973)PubMedGoogle Scholar
  24. Hoffman, N. E., Iser, J. E., Smallwood, R. A.: Hepatic bile acid transport: effect of conjugation and position of hydroxyl groups. Amer. J. Physiol.229, 298–302 (1975)PubMedGoogle Scholar
  25. Hofmann, A. F., Small, D. M.: Detergent properties of bile salts: Correlation with physiological function. Ann. Rev. Med.18, 433–476 (1967)CrossRefGoogle Scholar
  26. Iser, J. H., Dowling, R. H., Mok, H. Y. I., Bell, G. D.: Chenodeoxycholic acid treatment of gallstones. New Engl. J. Med.293, 378–383 (1975)PubMedGoogle Scholar
  27. Makino, I., Hashimoto, H., Shinozaki, K., Yoshino, K., Nakagawa, H.: Sulfated and nonsulfated bile acids in urine, serum and bile of patients with hepatobiliary diseases. Gastroenterology68, 543–553 (1975)Google Scholar
  28. McSherry, C. K., Morrissey, K. P., Swarm, R. L., May, P. S., Nieman, W. H., Glenn, F.: Chenodeoxycholic acid induced liver injury in pregnant and neonatal baboons. Ann. Surg.184, 490–499 (1976)PubMedGoogle Scholar
  29. Morrissey, K. P., McSherry, C. K., Swarm, R. L., Nieman, W. H., Deitrick, J. E.: Toxicity of chenodeoxycholic acid in the nonhuman primate. Surgery77, 851–860 (1975)PubMedGoogle Scholar
  30. Palmer, R. H.: Bile acids, liver injury and liver disease. Arch. intern. Med.130, 606–617 (1972)CrossRefPubMedGoogle Scholar
  31. Palmer, R. H.: Toxic effects of lithocholic acid on the liver and biliary tree. In: The hepatobiliary system (W. Taylor, (ed.)). New York-London: Plenum Press 1976Google Scholar
  32. Palmer, R. H., Bolt, M. D.: Bile acid sulfates I. Synthesis of lithocholic acid sulfates and their identification in human bile. J. Lipid Res.12, 671–679 (1971)PubMedGoogle Scholar
  33. Palmer, R. H., McSherry, C. K., May, P. S.: Lithocholate metabolism in baboons, ingesting chenodeoxycholic acid. Gastroenterology72, 1173 (1977)Google Scholar
  34. Portman, O. W.: Importance of diet, species and intestinal flora in bile acid metabolism. Fed. Proc.21, 896–902 (1962)PubMedGoogle Scholar
  35. Rufie, J.: Immunogenetics in man. Adv. Behav. Biol.9, 177–215 (1972)Google Scholar
  36. Salen, G., Dyrszka, H., Chen, T., Saltzman, W. H., Mosbach, E. H.: Prevention of chenodeoxycholic acid toxicity with lincomycin. Lancet 1975I, 1082CrossRefGoogle Scholar
  37. Sjövall, J.: Effect of dietary glycine and taurine on bile acid conjugation in man. Bile acids and steroids. 75. Proc. Soc. exp. Biol. (N.Y.)100, 676–678 (1959)Google Scholar
  38. Snyder, F., Kimble, H.: An automatic zonal scraper and sample collector for radioassay of thin-layer chromatograms. Analyt. Biochem.11, 510–518 (1965)CrossRefPubMedGoogle Scholar
  39. Stiehl, A.: Bile salt sulfates in cholestasis. Europ. J. clin. Invest.4, 59–63 (1974)PubMedGoogle Scholar
  40. Sturman, J. A., Hepner, G. W., Hofmann, A. F., Thomas, P. J.: Metabolism of (35S)taurine in man. J. Nutr.105, 1206–1214 (1975)PubMedGoogle Scholar
  41. Thistle, J. L., Hofmann, A. F.: Efficacy and specificity of chenodeoxycholic acid therapy for dissolving gallstones. New Engl. J. Med.289, 655–659 (1973)PubMedGoogle Scholar
  42. Thistle, J. L., Hofmann, A. F., Ott, B. J., Stephens, D. H.: Chenotherapy for gallstone dissolution I. Efficacy and safety. J. Amer. med. Ass. (in press)Google Scholar
  43. Watkins, J. B., Brown, E. R.: Conjugation and sulfation of lithocholic acid in fetal liver. In: Bile acid metabolism in health and disease (G. Paumgartner, A. Stiehl, eds.). Lancaster: MTP 1977Google Scholar
  44. Webster, K. H., Lancaster, M. C., Wease, D. F., Hofmann, A. F., Baggenstoss, A. H.: Influence of primary bile acid feeding on cholesterol metabolism and hepatic function in the rhesus monkey. Mayo Clin. Proc.50, 134–138 (1975)PubMedGoogle Scholar
  45. Weiner, M., Dayton, P. G., Hendrickz, A. G.: Drug disposition patterns in subhuman primates as compared to humans and other species. In: Use of nonhuman primates in drug evaluation (H. Vagtborg, ed.). Austin: Univ. of Texas Press 1968Google Scholar
  46. Williams, R. T.: Species variations in drug biotransformation. In: Fundamentals of drug metabolism and disposition (E. G. Mandel, E. L. Way, eds.). Baltimore: Williams and Wilkins 1971Google Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • M. Schwenk
    • 1
  • A. F. Hofmann
    • 2
  • G. L. Carlson
    • 3
  • J. A. Carter
    • 3
  • F. Coulston
    • 4
  • H. Greim
    • 1
  1. 1.Institut für Toxikologie, Gesellschaft für Strahlen- und UmweltforschungNeuherbergFederal Republic of Germany
  2. 2.U.S. Senior Scientist Awardee Alexander von Humboldt Foundation, Department of MedicineUniversity of California at San DiegoUSA
  3. 3.Gastroenterology UnitMayo Clinic and Mayo FoundationRochesterUSA
  4. 4.Institute of Comparative and Human ToxicologyAlbany Medical CollegeAlbanyUSA

Personalised recommendations